Senior Principal Scientist - Imaging

The Clinical Imaging Senior Principal Scientist for Oncology will own the strategy and execution of complex early through late-phase oncology imaging in clinical trials where imaging plays a key role. Imaging includes all modalities with a special focus on PET and CT. In this role, you will champion the development of imaging endpoints and biomarkers and drive the scientific imaging aspects as well as tumor response assessment of oncology clinical studies in partnership with clinical sciences and preclinical research teams.

• Create fit-for-purpose imaging biomarker strategies and work closely with research, clinical imaging and the oncology therapeutic area for the development of imaging endpoints to inform and advance the Regeneron clinical pipeline.

• Prepare and present clinical imaging strategies to senior management.

• Manage a complex network of stakeholders across Regeneron.

• Lead, design and implement multi-modality imaging measures as endpoints for oncology therapeutic clinical studies.

• Collaborate closely with Regeneron clinical teams as imaging subject matter expert to ensure optimal design and execution of imaging strategy including development of protocols, imaging endpoints, imaging manuals, imaging charters, statistical analysis plans and clinical study reports.

• Work closely with Clinical Imaging Operations and imaging contract research organizations to ensure the flawless conduct and data integrity of studies’ imaging components and endpoints.

• Serve as Study Scientific Lead for clinical trials focused on qualification and utilization of novel imaging biomarkers.

• Lead the interaction with regulatory agencies for communications regarding imaging endpoints and procedures.

• Lead the interaction with regulatory agencies and site ethics committees for approval of clinical imaging biomarker development studies

• Experience applying PET imaging as a quantitative endpoint in clinical or preclinical studies in Oncology.

• Direct experience with preclinical oncology imaging models using PET and immuno-PET imaging biomarkers to support drug development.

• Strong background in oncology, biology, molecular imaging, radiopharmaceuticals and familiar with precision medicine approaches.

• Imaging CRO oversight and implementation of quality control procedures highly desirable.

a PhD with a minimum of 6+ years of clinical imaging experience.

Experience implementing central efficacy assessments using tumor response criteria such as RECIST 1.1, iRECIST, PCWG3, Lugano and IMWG in oncology clinical trialsis required.

Does this sound like you? Apply now to take your first step towards living the Regeneron Way! We have an inclusive culture that provides comprehensive benefits, which vary by location. In the U.S., benefits may include health and wellness programs (including medical, dental, vision, life, and disability insurance), fitness centers, 401(k) company match, family support benefits, equity awards, annual bonuses, paid time off, and paid leaves (e.g., military and parental leave) for eligible employees at all levels!

For additional information about Regeneron benefits in the US, please visit  For other countries’ specific benefits, please speak to your recruiter.

Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, familial status, marital or registered civil partnership status, pregnancy or parental status, gender identity, gender reassignment, military or veteran status, or any other protected characteristic in accordance with applicable laws and regulations.

The Company will also provide reasonable accommodation to the known disabilities or chronic illnesses of an otherwise qualified applicant for employment, unless the accommodation would impose undue hardship on the operation of the Company's…